Open AccessExperimental and clinical evaluation by flow cytometry for the mechanism of combination therapy (cisplatin and peplomycin)
Author(s) -
Kawamoto Keiji,
Wada Yasuhiro,
Kumazawa Hirofumi,
Yamashita Toshio,
Kumazawa Tadami,
Matsumura Hiroshi
Publication year - 1992
Publication title -
cytometry
Language(s) - English
Resource type - Journals
eISSN - 1097-0320
pISSN - 0196-4763
DOI - 10.1002/cyto.990130313
Subject(s) - propidium iodide , cisplatin , flow cytometry , fluorescein isothiocyanate , combination therapy , in vivo , fluorescein , in vitro , staining , cell cycle , bromodeoxyuridine , cancer research , medicine , cell , chemistry , pharmacology , pathology , chemotherapy , immunology , apoptosis , biology , biochemistry , fluorescence , immunohistochemistry , programmed cell death , physics , microbiology and biotechnology , quantum mechanics
Pharmacologic effects of cisplatin (CDDP) and peplomycin (PEP) on tumor cell kinetics were studied bath in vitro and in vivo with the aid of flow cytometry (FCM). Double staining with propidium iodide (PI) and fluorescein isothiocyanate (FITC)‐labeled bromodeoxyuridine (BrdU) was used to analyze the cell cycle, and the number of viable cells was determined with fluorescein diacetate (FDA). Effects of combining the 2 agents were also studied to establish the most effective method of combination therapy. Furthermore, these agents were tried clinically on the basis of experimental results. Results showed that CDDP exerted its action at the S and G 2 M phases in the cell cycle and PEP at the G 2 M phase. Among the combination regimens in the experiments with CDDP, PEP, and CDDP + PEP as analyzed by FCM, the strongest block on the G 4 M phase was shown in the one at a 2‐day interval, resulting in the most effective killing of the tumor cells. Clinical trial of the combination therapy showed the same results as the in vitro experiment; the therapy proved useful for improving the patient's clinical condition and the results obtained with CT imaging and pathology.